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Regulatory Compliance of Labels and Product Information Leaflets for
Medicines Distributed in the Private Sector in South Sudan
S. Mawa 1, Z. Ekeocha 2, S. Byrn 3, K. Clase 4

ABSTRACT
Patient information leaflets (PILs) and labels are important for rational use of medicines as they provide additional
information for patients on the medicines dispensed to them. In developing countries, this potential cannot be fully
harnessed unless manufacturers provide medicines with labels and PILs that meet regulatory standards for
content and user-friendliness. In South Sudan, it is not known if manufacturers uphold standards of these labels
and PILs once their products are approved for distribution in the country.
This study explored the degree to which medicines distributed in South Sudan comply with regulatory requirements
for labels and PILs. A cross-sectional survey was conducted at selected pharmacies in Juba, the capital city of
South Sudan. Labels and PILs from tracer medicines (based on the WHO priority list of medicines for children and
women) were retrieved and assessed for compliance with regulatory requirements. Clients leaving the pharmacies
were also interviewed about their prescriptions and understanding of the PILs.
This study demonstrated that availability of essential medicines for maternal and child health is limited in the
private sector is limited (66% overall). Furthermore, the availability and quality of labels and PILs leave a lot to be
desired (79% complied with labeling requirements; 68% complied for PIL. There was a tendency for compliance
of products from certain countries to be particularly poor. PILs were given out for only 38% of medicines dispensed.
Most patients (92%) leaving the pharmacy did not know contraindications for the medicines dispensed, while
majority (83%) had no idea what they should do if they had forgotten to take their medicine on time.
Limited availability of essential medicines in the private sector has implications on universal health coverage, as
a good proportion of patients seek health care services through the private sector. Labels and PILs are essential
for education on their medication and impact on rational use of medicines. Moving forward, the regulatory authority
in South Sudan would benefit from establishing and implementing strict guidelines that compel importers to adhere
to licensing conditions related to labels and PILs up to the last mile of the supply chain. Frequent post-marketing
authorization inspections should be used to check on these aspects with punitive measures taken against noncompliant distributors.
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Medicine labels, patient information leaflets (PIL), medication errors, patient safety, regulatory compliance, rational
use of medicines.
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1. INTRODUCTION
For a patient to benefit from medicine given to him or
her, it is important that he or she knows what it is, why
it is prescribed, how it will work, what side effects to
expect, and what to do in case those side effects
occur. However, with increasing patient load, doctors
and dispensing staff may not have enough time to
counsel patients properly on the medicines
prescribed. Appropriate labels and patient information
leaflets (PILs) are therefore useful resources that can
fill the gap in patient education to promote rational use
of medicines, thereby promoting patient safety.
The PIL, as a form of written medication information,
is the most easily available, accessible, and important
material to provide to patients. Written medication
information is important to patients as it supports,
complements, and reinforces the verbal education
received at counseling, and can be kept for ongoing
reference (Mai & Aslani, 2007). Stichele (2004) who
reviewed Belgian patient information leaflets, noted
the vast majority of patients read them, and concluded
the leaflets have a positive impact on patient
satisfaction, regardless of their quality. This could be
because patients typically wish to know more about a
medicine’s indication, expected benefits, duration of
therapy, and an accurate list of potential adverse
effects (Jeetu & Girish, 2010).
Kenny et al. (1998) reviewed use of PILs, and
concluded that they can improve health outcomes
because, if used well, they can bridge the information
gap
identified
between
patient-physician
relationships. PILs are needed and demanded by
patients. Nathan et al. (2007) surveyed a total of 307
patients in their study and found that for new
medications, patients reported reading the leaflets
always (49%), often (21.2%), seldom (16.0%), or
never (13.7%). For refilled medications, respondents
reported reading the leaflets always (21.6%), often
(13.9%), seldom (26.4%), or never (38.2%). When
assessed for understandability, 267 (56.2%) of those
who responded reported the PIL was very easy to
understand, 34.5% reported somewhat easy, 8.5%
reported somewhat difficult, and 0.8% reported very
difficult to understand; 63.8% reported that the PIL
was useful, 35.0% reported somewhat useful, and
1.2% reported that the leaflet was not useful. They
therefore
recommended
pharmacists
should
encourage reading the leaflet and promote it as a
useful resource.
Despite evidence in support of use of PIL, a study
conducted in Jos city, Nigeria (Ogaji et al., 2013)
found that manufacturers of pharmaceuticals in
Nigeria were aware of the importance of the PILs in
promoting the safe and efficacious use of their

medicines. However, only few of them applied this
knowledge to the benefit of the users of their products.
A similar study in Abu Dhabi (Gharibyar et al., 2013)
found that information relevant to the safe and
appropriate use of medications was not uniformly
mentioned in the PILs analyzed. Additionally, of the
41 drug products obtained from online pharmacies
from 12 different countries, only one product met both
labeling and PIL guidelines for the United States
(Veronin, 2011).
Written medication information is important to patients
as it supports, complements, and reinforces the
verbal education received at counseling, and can be
kept for ongoing reference (Mai & Aslani, 2007).
Correct and clear labeling is important because
thousands of medication name pairs might be
confused or have been identified as having the
potential for confusion, based on similar appearances
or sounds when written or spoken (Berman, 2004).
Shrank et al., (2007) asserted that variability in drug
labeling and the use of difficult terminology can
adversely affect a patient’s understanding of
medication instructions. In an Australian study (Pit et
al., 2008) amongst elderly people living in the
community, 9% reported problems reading labels, 9%
reported difficulty remembering to take the medicine,
8% did not know what the medicine was prescribed
for, 6% had trouble understanding the label, and 10%
had difficulty opening the bottle or packaging.
Van Dooren et al (2015) carried out an online survey
with a panel of 785 Dutch pharmacy technicians and
discovered patients mostly asked questions related to
drug actions, problems with use, side effects,
intolerances, and pregnancy and lactation. This was
attributed to the PILs not providing enough
information on these issues, or the patients not finding
the PIL easy to read, understand, or recall. In another
study, Shivkar (2009) further found that although
warnings and precautions were included in a majority
of PILs, they rarely mentioned information regarding
pediatric use (43.8% of PILs), geriatric use (12.5% of
PILs), or use in special conditions, such as liver, renal,
cardiac, and other relevant conditions (38.8% of
PILs).
This problem is not unique to generics. Gharibyar et
al (2013) reviewed 67 PILs for branded (72%) and
generic (28%) prescription-only medicines from
different countries (USA, UAE, Sweden, France, UK,
Japan, Germany, Canada, and Belgium) that were
distributed in the Emirate of Abu Dhabi. The study
demonstrates that of the PILs analyzed, only 35
(52.2%) out 67 contain clinically relevant information
that was required by the Ministry of Health, while 32
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(47.8%) failed in one or more of the 14 parameters
evaluated.
It is therefore apparent it is uncommon to find
complete lack of, or variability in, quality of packaging
information inserts and product labeling that may
negatively affect patient access to vital information.
Several factors may be responsible, such as weak
manufacturers’ quality assurance system to ensure
consistent compliance with marketing authorization

requirements, poor regulatory oversight to detect,
investigate, and sanction omissions, or various
factors in the supply chain (e.g., illegal importation,
sourcing from unlicensed distributors, counterfeiting,
etc.).
Figure 1 below illustrates the general context and
responsibilities to ensure good flow of medicine
information, including accompanying labels and PILs,
from manufacturers to the ultimate user (patient).
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Figure 1: Context and Concept of the Project

In humanitarian and fragile contexts such as South
Sudan, where regulatory oversight and postmarketing surveillance mechanisms are weak, every
effort must be made to avail user-friendly
information, including appropriate labels and PILs.
However, manufacturers and their agents may
disregard or compromise the quality of packaging
information leaflets and labels once products are
registered and authorized for distribution.
This study aimed to measure:
a) availability of tracer medicines in private
pharmacies;
b) proportion of tracer medicines that were
compliant with regulatory standards for
labels and PILs;

c) proportion of patients who read the PILs
provided with new or refilled medications;
d) proportion of patients who understood the
content of the label and PILs for medicines
dispensed to them.

2. METHODS
The study explored the relationship between
availability of regulatory complaint labels and P, and
patient comprehension of medicine information and
rational use of products. Consideration was also
given to examine moderating factors such as
patient’s level of education and sufficiency of patient
counseling by dispensers.
A cross-sectional survey was conducted, collecting
both quantitative and qualitative data from samples
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purposively drawn from willing pharmacies in Juba,
the capital city of South Sudan. Data was collected
in one week in April 2018
The following approach was used for sampling and
data collection:
•

•

•

•

Selection of tracer medicines: Products on the
World Health Organization (WHO) list of priority
medicines for children and women (World Health
Organization, 2012), or the UN Commission for
Life Saving Commodities Report (United
Nations, 2012) were selected. All the 17 eligible
tracer medicines were asked for on the day of the
survey at the pharmacies where data was
collected. Where any of the tracer medicines
were missing, no replacement was done with
other products. However, to keep the sample
size reasonable, it was decided for availability
below 50%, an alternative pharmacy with better
stock levels of the tracer medicines would be
considered.
Selection of pharmacies: Pharmacies were
purposively selected based on their willingness
to cooperate and allow data collection from their
premises. Attempts were made to select at least
one pharmacy in each of the 3 major Payams for
Juba City Council. Data was collected from 5
pharmacies. One of these pharmacies also had
a wholesale section, and another had a clinic in
addition to the retail pharmacy. Consent for the
assessment was obtained from all the in-charges
at the five premises.
Selection of labels and PILs: Labels and PILs
to be reviewed were selected at two points: a)
from the tracer medicines sampled for
assessment of regulatory compliance; b) from
dispensed packs of patients leaving the
pharmacy. About 20-30 labels and PILs for tracer
medicines and/ or those dispensed to patients
were targeted for review, per pharmacy outlet,
where data was collected. The labels and PILs
were evaluated for compliance of with the
European Commission Directive 2001/83/EC
(European Economic Community, 1992) since
South Sudan had not yet developed countryspecific guidelines.
Selection of patients for exit interviews: All
patients who received any medicine dispensed
from the collaborating pharmacy at the time of
data collection were offered the opportunity to
participate, with informed consent taken.
Patients were selected sequentially on the day of
the survey for interviews. For illiterate patients
collecting medicines from the pharmacies, an
accompanying attendant, if available, was given
the PILs and asked questions. About 10-15

patients were targeted to be interviewed in exit
interviews, per pharmacy outlet.
The tools used were validated in prior studies, but
pre-testing was done to assess how well the adapted
versions would apply to the local context:
•
•

•

Checklist by Pires et al., (2015) for assessing
regulatory compliance of the labels and PILs with
the EC Directive 2001/83/EC.
Flesh Readability Ease (FRE) formula, with
reading scores on FRE scale are 0-100, for
assessing patient comprehension of labels and
PILs. Scores between 90 and 100 were
considered easily understandable by an average
5th grader; between 60 and 70 were considered
easily understood by 8th and 9th graders; and
scores between 0 and 30 were considered easily
understood by college graduates. The scores
between 60 and 70 were largely considered
acceptable ((Spadaro et al., 1980; Adepu R., and
Swamy M.K., 2012).
The Baker Able Leaflet Design (BALD) Method
(Baker S., 1997; Shareef et al., 2016) was used
to assess the layout and design characteristics
of the patient information leaflets. The scores
were based on the length of the line, distance
between the line, letter font size, graphics used,
percent of white space, and paper quality. The
document is considered to have a good layout
and design if it scored 25 or more.

The study did not collect private identifiable
information. However, IRB approval for the study
was obtained from the Purdue Ethics Committee
(IRB# 1602017223).

3. RESULTS AND DISCUSSION
All the pharmacies were licensed by the regulatory
authority. However, none of the superintendent
pharmacists were present at time of assessment.
Two had pharmacy technicians, while three had
nurses in charge at time of assessment. The main
sources of medicines for the pharmacies were
imports from Egypt, India, and neighboring East
African countries. Copies of importation documents
were maintained on file at the premises.
Not all pharmacies prioritized inventory of essential
medicines the way it is understood at the global level.
Overall availability of the tracer medicines per
pharmacy visited was 66%. Over 38% (14/37) of the
tracer products had availability of less than, or equal
to, 60%. Out of the 37 tracer medicines assessed,
seven (19%) that require experts to administer in
clinic settings (e.g., IUDs, calcium gluconate
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injection, magnesium sulphate injection, misoprostol,
oxytocin, and Ringer’s lactate) were out of stock in all
the pharmacies visited. This is probably because
clinics in South Sudan generally do not refer
prescriptions to pharmacies.

S/
No.

Product

TM
-05

Artesunate 60mg/vial
Injection

100%

82%

82%

TM
-06

Sulphadoxine+Pyrime
thamine
500/25mg
Tablet

80%

80%

62%

TM
-07

Male Condoms

100%

64%

17%

TM
-08

Female Condoms

0%

0%

0%

TM
-09

Oral Contraception –
COC e.g. Microgynon

80%

72%

20%

TM
-10

Oral Contraception –
POP e.g. MIcrolut35

40%

82%

41%

TM
-11

Injectables – DepoProvera

60%

79%

62%

TM
-12

Injectables – Sayana
Press

0%

0%

0%

TM
-13

IUDs

0%

0%

0%

TM
-14

Implants - Jadelle

40%

84%

42%

TM
-15

Implants - Implanon

60%

85%

0%

TM
-16

Emergency
contraception 1.5mg
(x1) or 0.75mg(x2)

100%

71%

68%

TM
-17

Ampicillin injection

100%

81%

83%

TM
-18

Amoxicillin dispersible
tablets, 250mg

100%

82%

83%

TM
-19

Azithromycin tablets

100%

84%

83%

TM
-20

Benzathine
benzylpenicillin
injection

100%

83%

80%

TM
-21

Dexamethasone inj

80%

81%

61%

TM
-22

Betamethasone inj

80%

81%

60%

TM
-23

Calcium
injection

0%

0%

0%

TM
-24

Cefixime 400mg tablet

100%

82%

87%

Details of individual availability, and label and PIL
compliance for each tracer medicine are presented
in Table 1 below.

TM
-25

Chlorhexidine solution

80%

79%

42%

TM
-26

Gentamicin injection

100%

80%

65%

Table 1: Availability of Tracer Medicines in Pharmacies

TM
-27

Hydralazine injection

100%

83%

63%

TM
-28

Magnesium
injection

0%

0%

0%

TM
-29

Methyldopa tablet

100%

78%

64%

TM
-30

Metronidazole
injection

100%

84%

86%

TM
-31

Misoprostol tablet

0%

0%

0%

TM
-32

Nifedipine
capsule

100%

61%

85%

TM
-33

Oral Rehydration Salt
(ORS)

100%

79%

59%

Availability of contraceptives was 100% for male
condoms and emergency contraceptive pills, while
Microgynon had availability 80%, Depo-Provera
60%, Implanon 60%, Jadelle 40%, and Microlut 40%.
However, none of the pharmacies visited had female
condoms, Sayana Press, or IUDs. Other life-saving
maternal health medicines, such as oxytocin,
misoprostol, magnesium sulphate, and calcium
gluconate, which are vital for emergency obstetrics
care, were not on the shelves at all. Essential child
health medicines such as oral rehydration salt and
zinc sulphate (for acute watery diarrhea) and
dispersible amoxicillin (for pneumonia) were 100%
available, while dispersible antimalarials were only
available in 60% of pharmacies.
The selected tracer medicines address the biggest
public health needs essential for reducing maternal
and child mortality (Bigdeli et al., 2015). Access to
such essential medicines is particularly critical in a
country like South Sudan, where the World Bank and
UN (2015) estimated maternal and child mortality to
be 789/100,000 and 62/1000 respectively, ranking
among the highest in the world. Availability and
hence access through both public and private sector
channels should be promoted for universal health
coverage.
Labels were examined for a total of 97 products that
were available in the four pharmacies, which gave
consent for further assessment. Overall compliance
was 79%. However, only 68% of PILs from these 97
products were found to be compliant with regulatory
requirements.

S/
No.
TM
-01

Product
Artemether
+
Lumefantrine
20/120mg, 24 tablets

TM
-02

Artemether
+
Lumefantrine
20/120mg, 18 tablets

TM
-03

Artemether
+
Lumefantrine
20/120mg, 12 tablets

TM
-04

Artemether
+
Lumefantrine
20/120mg, 6 tablets

Availabilit
y

80%

80%

20%

60%

Label
Compliance

80%

80%

27%

80%

PIL
Compliance

61%

61%

40%

59%

Availabilit
y

gluconate

sulfate

tablet/

Label
Compliance

PIL
Compliance
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S/
No.

Product

Availabilit
y

TM
-34

Oxytocin injection

0%

0%

0%

TM
-35

Sodium
lactate
compound solution

0%

0%

0%

TM
-36

Sodium chloride IV
solution

100%

80%

48%

TM
-37

Zinc sulfate tablet

100%

77%

75%

79%

68%

Average score per
pharmacy
visited
(%)

Label
Compliance

PIL
Compliance

66%

Most of the products were manufactured in in India
(59%), followed by China (31%). Few of them were
from European countries such as Belgium (3%),
Netherlands (3%), or Hungary (1%). A small
proportion of products came from African countries:
Kenya (1%) and Egypt (1%). Overall regulatory
compliance of product labels was 79%. Hence using
this as the minimum benchmark for a product to be
considered compliant with labeling requirements by
country of origin, it was noted only products from
India (60%) were not compliant. In the same vein,
considering the overall average for compliance with
PIL requirements (68%) as the benchmark required
for a product to be considered compliant with PIL
requirements by country of origin, all products from
other countries were 100% compliant, except India
(57%).
Details of products by country of origin, and
compliance with label and PIL requirements are
presented in Table 2 below:

from these countries to curb poorly labeled products
from entering the domestic supply chain.
In total, prescriptions from 13 patients, who left 4
pharmacies, were reviewed. The average products
per prescription was 2.3, which is within acceptable
limits for rational use of medicines, which is 2 to 3
medicines per patient per encounter according to
WHO World Medicine Situation (2011). All the
medicines were labeled prior to dispensing, but only
38% patients received PILs for all of their
medications. This means once at home, patients had
nothing to refer in case they forgot instructions given,
or if they experienced side effects.
Details are summarized in Table 3 below.
Table 3: Review of Quality of Prescriptions
#
All
Pharmacy Patient # Prescribed labeled?
P-01

5

1

0

P-02

2

1

0

P-03

2

1

1

P-04

2

1

1

P-01

3

1

0

P-02

3

1

1

P-03

2

1

0

P-04

2

1

0

P-01

3

1

0

P-02

2

1

1

P-03

1

1

0

P-04

1

1

1

P-01

2

1

0

Total

30

13

5

Average

2.3

100%

38%

1

2

Table 2: Variation in product availability and compliance with
labeling and PIL requirements by country of origin
Products in
Stock

Labeling
Compliance

#

%

#

%

#

%

India

57

59

34

60

32

56

China

30

31

29

97

22

73

Belgium

3

3

3

100

3

100

Egypt

2

2

2

100

2

100

Netherlands

3

3

3

100

3

100

Kenya

1

1

1

100

1

100

Hungary

1

1

1

100

1

100

Total

97

100

73

75

64

66

Country

PIL Compliance

With India and China, the main source of medicines
in the private sector, it is important the DFCA applies
risk-based screening and inspections on imports

All
with
leaflet?

3

4

Client exit interviews were conducted with 12
patients from four pharmacies (same ones that
provided PILs and allowed examination of labels
from
their
premises).
The
demographic
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characteristics of the patients are summarized in
Table 4 below.
Table 4: Demographic Characteristics of Patients Interviewed
Sex

Age

Mother tongue

Present occupation

Education

Self-assessed reading ability

Male

8

0-19

2

Acholi

1

Businessman

3

Primary school

2

Fair

5

Female

4

20-29

4

Bari

3

Housewife

1

Secondary school (O-Level)

5

Good

6

30-39

3

Dinka

3

Social worker

1

Secondary school (A-Level)

2

Nil

1

³40

3

Jur

1

Soldier

2

University

2

Kakwa

1

Student

3

Other (never been to school)

1

Kuku

1

Teacher

2

TOTAL

12

12

12

All patients who received PILs with their dispensed
medicines retained them, but only one read parts of
the PIL before leaving the dispensing window, while
the rest claimed they would read from home. Majority
of the patients (83%) claimed they had previously
used the medicines dispensed. When probed further
if they normally read the PILs that come with their
medicines, only 2 (16%) responded “Always,” with
the rest responding with “Rarely” (58%) and “Never”
(26%). All the patients interviewed had however
asked the pharmacy staff about their medicine.
Nevertheless, almost all (11 out of 12 [92%]) did not
know if there were any occasions when the medicine
should not be used. Additionally, 10 out of 12 (83%)
were not sure what they should do if they forgot to
take their medicine on time.
Review of patient understanding of PILs was done
with four patients, who were willing to spend more
time to read and answer questions on the PILs at the
premises.
Table 5: Patient Understanding of PILs
Leaflet aspects assessed

Patient Responses

1.

Too small (1) – 25%

The letters in the text are:

Right size (3) – 75%
Too small (1) – 25%

12

12

12

2.

The distances between the lines Right size (3) – 75%
are:

3.

The sentences in the text are 100% right
(length):

4.

The sentences in the text are Easy (2) – 50%
(comprehension):
Difficult – 50%

5.

Are there any words in the text Few (1) – 25%
that you do not understand
Many (3) – 75%

6.

Does the leaflet lack illustrations? Don't know (3) – 7 5%
No (1) – 25%

7.

What does the leaflet say about the following?
a) What is the medicine 100% understood
used for?
b) How should you take it?

100% understood

c) In what way does the 50% understood
medicine act (work)?

8

d) What is the name of the 67% understood
company that produces the
medicine?
8.

Is there any other medicine that 25% understood, and
should not be taken together with knew the medicines
your medicine?
that should not be
taken together

9.

Can your medicine be taken if the patient:
Is pregnant?

50% Don't know

Is breastfeeding?

50% Don't know

Is going to drive a car?

50% Don't know

Has drunk alcohol?

50% Don't know

10. What do you do if you have taken All did not know
too much medicine?
11. Which side effects can your 50% knew few side
effects
associated
medicine give/ cause?
with their medicines
12. Are there any recommendations 75% knew storage
on how you should store your conditions for their
medicine?
medicines
13. Is there anything that you would No (4) – 100%
like to know about your medicine,
which you cannot find in the
leaflet?
14. To find what I was looking for in Very difficult (1) – 25%
the text was

become more crucial with the growth of internet
pharmacy and quality risks associated with it. For
instance, in a similar study, Veronin (2011) obtained
and evaluated a total of 41 drug products sourced
from online pharmacies from 12 different countries
and concluded only one product (from Canada)
would meet both labeling and PIL guidelines for
products allowed to be dispensed in the United
States. This suggests labeling and packaging
practices for some medicines sold online may be
inferior to the high standards in the United States.
Another area to strengthen as part of good
dispensing practices is the checking for patient
understanding. At the moment, reading of PILs is
very poor (only 16% always read them). This study
showed patients may not understand instructions
given at time of dispensing, but may fear to ask
questions. Dispensers need to ask patients to relay
back the information the way they understand it.
They also need to orient patients on how and where
they can find specific information on their patient
information leaflets. This is particularly important in
relation to side effects, contra-indications,
interactions, dosage, and actions to take when doses
are forgotten.
Finally, for PILs to be effective for patient education,
they should be in simple language. Idris et al. (2014)
who conducted a study among Sudanese community
and hospital pharmacists cited texts’ language
(68.2%), technical terminology (75%), and font size
(10%) as main barriers to understandability.
Therefore, to secure usefulness of PILs, PILs should
be written in lay terminology.

Difficult (1) – 25%

4. CONCLUSION

Easy (2) – 50%

This exploratory study provides preliminary insight
into the issues impacting access to life-saving
medicines that are key to reducing maternal and child
mortality in South Sudan. It also demonstrated gaps
in the regulatory system, where the absence of a
formal drug registration process leaves room for
uncontrolled imports and potential dumping of
counterfeit/sub-standard products in the country.

15. I think that the leaflet as a whole Easy (3) – 75%
is:
Difficult (1) – 25%
16. Any suggestions for improving No idea (1) – 25%
the leaflet to make it easier for
you to understand?
Fine (2) – 50%
Make bigger (1) – 25%

These findings underscore the need for medicine
regulation to go beyond legislating. It is important to
create a regulatory enforcement and sanctions
culture that will ensure manufacturers comply with
conditions for marketing authorization. This will

At the point of use, the study revealed several areas
for improvement to ensure patients are empowered
to use their medicines correctly for optimal
therapeutic benefits. Dispensed medicines should be
well labeled and accompanied by patient information
leaflets that are easy to read and understand.
Pharmacy staff should take time to educate patients
on their medicines and encourage them to read the
PILs.
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5. RECOMMENDATIONS
STEPS

FOR

NEXT

This study highlights existing regulatory and practice
gaps in use of patient information leaflets and
labeling for essential medicines distributed in Africa,
and South Sudan in particular. The findings can
support advocacy and campaigns that aim to:
a) encourage manufacturers to improve the
quality of their labels and patient information;
b) improve patient understanding of their
medicines,
hence
promote
rational
medication use;
c) reduce medication errors and improve
therapeutic outcomes;
d) enhance overall patient safety.
The South Sudan Drug and Food Authority (DFCA)
should put in place some mechanism for control of
quality of products imported into the country even
before a system of drug registration can be
established. Developing a system for product
notification can be a good starting point to ensure
only notified products are allowed to be imported and
distributed in the country. This can be followed for
post-marketing surveillance that regularly assesses
compliance of products in the market with minimum
labeling and PIL requirements, and sanctions noncompliance.
Future studies with bigger and random sampling will
be necessary to quantify and generalize the extent of
the problem with poor quality of labels and PILs.
Such studies should improve the data collection tools
to capture more detailed differences in regulatory
compliance and patient knowledge and practices in
making use of product labels and PILs.
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